Fat-Reducing Fragment
AOD-9604 is a modified growth hormone fragment that directly stimulates fat cells to release stored fat for burning, without raising blood sugar, triggering cell growth, or affecting insulin in any way. It has cleared multiple clinical trials with an excellent safety record and is registered as a therapeutic compound in Australia.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
30 mg
Format
Injectable
Composition
10 mg/ml per ml
AOD-9604 binds to the beta-3 adrenergic receptor in adipose tissue, stimulating lipolysis (the breakdown of stored triglycerides into free fatty acids and glycerol) without stimulating the IGF-1 axis that drives growth. This means it does not promote cell proliferation or insulin resistance, making it safe for metabolically sensitive individuals. It specifically targets visceral and subcutaneous adipose depots, inhibits lipogenesis (new fat synthesis), and has been shown to support fat oxidation independently of caloric restriction.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
AOD-9604 isolates the fat-burning properties of HGH without triggering IGF-1 production, cell growth, or insulin resistance. This makes it the safest HGH-derived fat loss option: providing targeted adipose tissue reduction without systemic anabolic or metabolic side effects.
AOD-9604 activates beta-3 adrenergic receptors in adipose tissue, stimulating hormone-sensitive lipase and releasing stored triglycerides as free fatty acids for oxidation. This receptor-selective mechanism mimics the direct fat-mobilising effect of HGH without the associated glucose dysregulation.
In addition to promoting fat breakdown, AOD-9604 inhibits fatty acid synthase (FAS): the enzyme responsible for synthesising new fat from dietary substrate. This dual action (stimulate lipolysis + block lipogenesis) creates a more comprehensive anti-adiposity effect.
Clinical data suggests AOD-9604 preferentially targets visceral adipose tissue (the metabolically active deep abdominal fat most strongly associated with cardiovascular and metabolic disease risk) rather than superficial subcutaneous fat.
Surprising secondary research has documented AOD-9604's ability to stimulate cartilage repair. Studies indicate it may activate pathways involved in proteoglycan and collagen synthesis in cartilage tissue: potentially extending its applications beyond pure fat loss.
AOD-9604 has been through multiple Phase 1 and Phase 2 clinical trials (as an anti-obesity drug) with no significant safety concerns identified. It is one of the most clinically evaluated peptide fat-loss compounds and is TGA-registered in Australia.
Explore selected publications on AOD-9604, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Preclinical study
AOD-9604 mechanism or target context
Publication and key finding
The synthetic C-terminal peptide fragment of human growth hormone, Leu-Arg-Ile-Val Gln-Cys-Arg-Val-Ser-Glu-Gly-Ser-Cys-Gly-Phe (hGH 177-191), was shown to have antilipogenic activity identical with that of the intact molecule of human growth hormone (hGH).
Biochemistry and molecular biology international
Evidence type
Preclinical study
AOD-9604 mechanism or target context
Publication and key finding
The effect of a synthetic C-terminal peptide sequence of human growth hormone, Leu-Arg-Ile-Val-Gln-Cys-Arg-Val-Ser-Glu-Gly-Ser-Cys-Gly-Phe (hGH 177-191) on glucose transport in adipocytes isolated from genetically-obese Zucker rats was investigated.
Biochemistry and molecular biology international
Evidence type
Review
AOD-9604 mechanism or target context
Publication and key finding
The ability of growth hormone (GH) to induce adipose tissue lipolysis has been known for over five decades; however, the molecular mechanisms that mediate this effect and the ability of GH to inhibit insulin-stimulated glucose uptake have scarcely been documented.
Nature reviews. Endocrinology
Evidence type
Preclinical study
Direct or closely related AOD-9604 evidence
Publication and key finding
A synthetic analogue (AOD9604) of the lipolytic domain of human growth hormone (hGH) has been studied for its metabolic actions in obese Zucker rats.
Hormone research
Evidence type
Preclinical study
AOD-9604 mechanism or target context
Publication and key finding
A lipolytic domain (AOD9401) of human growth hormone (hGH) which resides in the carboxyl terminus of the molecule and contains the amino acid residues 177-191, has been synthesized using solid-phase peptide synthesis techniques.
Journal of molecular endocrinology
Combinations used in research protocols where AOD-9604 complements other compounds.
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
AOD-9604 has an excellent safety profile documented across multiple clinical trials and regulatory submissions. Phase 1 and Phase 2 studies found no significant adverse effects on glucose metabolism, IGF-1 levels, or cardiovascular parameters. Mild injection site reactions (transient redness or swelling) are the most commonly reported effects. Unlike full HGH, AOD-9604 does not cause water retention, carpal tunnel symptoms, or glucose impairment. It is registered as a therapeutic compound in Australia and has been used in clinical settings for obesity management.
Other products from the same range
